Related Experiment Video
Updated: Jul 4, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Management of acute coronary syndromes in patients with renal dysfunction
Chiara Melloni1, Kenneth W Mahaffey
1Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA. mello004@mc.duke.edu
Insights
Patients with chronic kidney disease (CKD) and acute coronary syndromes (ACS) face higher mortality. Aggressive treatment may improve outcomes, but accurate kidney function assessment is crucial for medication dosing.
Area of Science:
- Cardiology
- Nephrology
- Clinical Trials
Background:
- Chronic kidney disease (CKD) is increasingly prevalent in patients with acute coronary syndromes (ACS).
- CKD is linked to significant cardiovascular morbidity and mortality.
- CKD patients are often excluded from clinical trials, limiting evidence for treatment decisions.
Purpose of the Study:
- To review recent findings on CKD in ACS patients.
- To highlight the impact of CKD on outcomes and treatment strategies.
- To emphasize the need for accurate renal function assessment and further research.
Main Methods:
- Review of recent studies and clinical trial data.
- Analysis of outcomes in ACS patients with varying degrees of renal function.
- Evaluation of current treatment guidelines and evidence gaps.
Main Results:
- CKD is an independent risk factor for adverse outcomes in ACS.
- Mortality risk increases progressively with declining glomerular filtration rate.
- Aggressive treatment strategies may yield outcomes comparable to non-CKD patients.
- Accurate renal function estimation is often overlooked, impacting medication dosing.
Conclusions:
- CKD stages correlate with in-hospital outcomes and evidence-based therapy use in ACS.
- Kidney function assessment is vital for appropriate antithrombotic drug dosing.
- Further clinical trials are needed for optimal management of CKD patients with moderate-to-severe kidney dysfunction during ACS.
Purpose Of Review:
Chronic kidney disease is becoming common among patients with acute coronary syndromes and is associated with substantial cardiovascular morbidity and mortality. Often, patients with chronic kidney disease are excluded from clinical trials, so in clinical practice physicians may not have definitive evidence to support treatment decisions.
Recent Findings:
Recent studies have shown that chronic kidney disease is an independent risk factor for outcomes in patients with acute coronary syndromes and that there is a stepwise increase in mortality with progressive decline of glomerular filtration rate. It has been demonstrated that the use of aggressive treatment strategies in these patients may be associated with improved outcome that is similar to, if not higher than, in those patients without renal disease. Yet, although critical for the correct dose adjustment of many antithrombotic and antiplatelet therapies, accurate renal function estimation often is not done.
Summary:
Chronic kidney disease is common, and the stages of chronic kidney disease are strongly related to the risk of adverse in-hospital outcomes and to the use of evidence-based therapies. Many antithrombotic drugs are eliminated mainly by the kidneys, so an accurate assessment of renal function is required in all patients with acute coronary syndromes for a proper dose adjustment. There is a clear need for clinical trials in patients with moderate-to-severe kidney dysfunction to further refine their optimal management in the setting of acute coronary syndromes.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:20Acute Kidney Injury V: Interprofessional Care
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:26Acute Coronary Syndrome V: Nursing Management
01:22Acute Kidney Injury VI: Nursing Management
01:28Chronic Kidney Disease III: Interprofessional Care